Ibrance 75 MG tablet 7S
Ended Awarded
- Contract number
- SPE2DB25FQZ90
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $8,124
Award facts
- Contract value 100% obligated
- $8,123.96 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $8,123.96 on June 9, 2025, for the supply of Ibrance 75 mg tablets (quantity 7 units). This is a firm fixed price delivery order with no set-aside designation, indicating the award was made through open competition. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 1, 2025. This delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion prime vendor agreement running through December 2026 that serves as the company's comprehensive global pharmaceutical support vehicle for military healthcare programs.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement through the DLA Medical Supply Chain, supplying brand-name and generic medications, vaccines, and specialized healthcare commodities. The company's federal contract portfolio demonstrates extensive capability to fulfill diverse pharmaceutical requirements across multiple therapeutic domains for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The Ibrance supply under this delivery order supports ongoing military healthcare operations requiring this oncology medication as part of the broader pharmaceutical support services delivered through the DLA prime vendor program.
Quick answers
Who was awarded contract SPE2DB25FQZ90?
SPE2DB25FQZ90 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on June 9, 2025.
How much is contract SPE2DB25FQZ90 worth?
The government has obligated $8,124 on SPE2DB25FQZ90.
Is contract SPE2DB25FQZ90 an order under another contract?
Yes. SPE2DB25FQZ90 is a delivery order under SPE2DB22D3004, an indefinite delivery contract.
Was contract SPE2DB25FQZ90 competed?
The extent of competition for SPE2DB25FQZ90 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award